RATIONALE: Group II metabotropic glutamate receptor (mGluR) agonists represent a novel approach to the treatment of schizophrenia. Inasmuch as the peptide neurotransmitter N-acetylaspartylglutamate (NAAG) activates these receptors, NAAG peptidase inhibitors conceptually represent a parallel path toward development of new antipsychotic drugs. While group II agonists are effective in several animal models of schizophrenia, they are reported to lack efficacy in moderating the effects of phencyclidine (PCP) on prepulse inhibition of acoustic startle in animal models of sensory processing deficits found in this disorder. OBJECTIVE: The objective of this study was to re-examine the efficacy of a group II metabotropic glutamate agonist and NAAG peptidase inhibitors in prepulse inhibition models of schizophrenia across two strains of mice. METHODS: The method used was an assay to determine the efficacy of these drugs in moderating the reduction in prepulse inhibition of acoustic startle in mice treated with PCP and D: -amphetamine. RESULTS: The group II agonist LY354740 (5 and 10 mg/kg) moderated the effects of PCP on prepulse inhibition of acoustic startle in DBA/2 but not C57BL/6 mice. In contrast, two NAAG peptidase inhibitors, ZJ43 (150 mg/kg) and 2-PMPA (50, 100, and 150 mg/kg), did not significantly affect the PCP-induced reduction in prepulse inhibition in either strain. CONCLUSIONS: These data demonstrate that the efficacy of group II agonists in this model of sensory motor processing is strain-specific in mice. The difference between the effects of the group II agonist and the peptidase inhibitors in the DBA/2 mice may relate to the difference in efficacy of NAAG and the agonist at mGluR2.
RATIONALE: Group II metabotropic glutamate receptor (mGluR) agonists represent a novel approach to the treatment of schizophrenia. Inasmuch as the peptide neurotransmitter N-acetylaspartylglutamate (NAAG) activates these receptors, NAAG peptidase inhibitors conceptually represent a parallel path toward development of new antipsychotic drugs. While group II agonists are effective in several animal models of schizophrenia, they are reported to lack efficacy in moderating the effects of phencyclidine (PCP) on prepulse inhibition of acoustic startle in animal models of sensory processing deficits found in this disorder. OBJECTIVE: The objective of this study was to re-examine the efficacy of a group II metabotropic glutamate agonist and NAAG peptidase inhibitors in prepulse inhibition models of schizophrenia across two strains of mice. METHODS: The method used was an assay to determine the efficacy of these drugs in moderating the reduction in prepulse inhibition of acoustic startle in mice treated with PCP and D: -amphetamine. RESULTS: The group II agonist LY354740 (5 and 10 mg/kg) moderated the effects of PCP on prepulse inhibition of acoustic startle in DBA/2 but not C57BL/6 mice. In contrast, two NAAG peptidase inhibitors, ZJ43 (150 mg/kg) and 2-PMPA (50, 100, and 150 mg/kg), did not significantly affect the PCP-induced reduction in prepulse inhibition in either strain. CONCLUSIONS: These data demonstrate that the efficacy of group II agonists in this model of sensory motor processing is strain-specific in mice. The difference between the effects of the group II agonist and the peptidase inhibitors in the DBA/2 mice may relate to the difference in efficacy of NAAG and the agonist at mGluR2.
Authors: L S Pilowsky; R A Bressan; J M Stone; K Erlandsson; R S Mulligan; J H Krystal; P J Ell Journal: Mol Psychiatry Date: 2006-02 Impact factor: 15.992
Authors: B S Slusher; J J Vornov; A G Thomas; P D Hurn; I Harukuni; A Bhardwaj; R J Traystman; M B Robinson; P Britton; X C Lu; F C Tortella; K M Wozniak; M Yudkoff; B M Potter; P F Jackson Journal: Nat Med Date: 1999-12 Impact factor: 53.440
Authors: Joseph H Neale; Rafal T Olszewski; Laura M Gehl; Barbara Wroblewska; Tomasz Bzdega Journal: Trends Pharmacol Sci Date: 2005-09 Impact factor: 14.819
Authors: Tomasz Bzdega; Samantha L Crowe; Epolia R Ramadan; Kathryn H Sciarretta; Rafal T Olszewski; Olumide A Ojeifo; Victoria A Rafalski; Barbara Wroblewska; Joseph H Neale Journal: J Neurochem Date: 2004-05 Impact factor: 5.372
Authors: Joseph H Neale; Rafal T Olszewski; Daiying Zuo; Karolina J Janczura; Caterina P Profaci; Kaleen M Lavin; John C Madore; Tomasz Bzdega Journal: J Neurochem Date: 2011-07-01 Impact factor: 5.372
Authors: Dean T Acheson; Murray B Stein; Martin P Paulus; Mark A Geyer; Victoria B Risbrough Journal: Neuropharmacology Date: 2012-05-02 Impact factor: 5.250
Authors: R T Olszewski; K J Janczura; S R Ball; J C Madore; K M Lavin; J C-M Lee; M J Lee; E K Der; T J Hark; P R Farago; C P Profaci; T Bzdega; J H Neale Journal: Transl Psychiatry Date: 2012-07-31 Impact factor: 6.222